Jump to navigation Jump to search
Clinical data
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass307.385 g/mol

WikiDoc Resources for Ibopamine


Most recent articles on Ibopamine

Most cited articles on Ibopamine

Review articles on Ibopamine

Articles on Ibopamine in N Eng J Med, Lancet, BMJ


Powerpoint slides on Ibopamine

Images of Ibopamine

Photos of Ibopamine

Podcasts & MP3s on Ibopamine

Videos on Ibopamine

Evidence Based Medicine

Cochrane Collaboration on Ibopamine

Bandolier on Ibopamine

TRIP on Ibopamine

Clinical Trials

Ongoing Trials on Ibopamine at Clinical Trials.gov

Trial results on Ibopamine

Clinical Trials on Ibopamine at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Ibopamine

NICE Guidance on Ibopamine


FDA on Ibopamine

CDC on Ibopamine


Books on Ibopamine


Ibopamine in the news

Be alerted to news on Ibopamine

News trends on Ibopamine


Blogs on Ibopamine


Definitions of Ibopamine

Patient Resources / Community

Patient resources on Ibopamine

Discussion groups on Ibopamine

Patient Handouts on Ibopamine

Directions to Hospitals Treating Ibopamine

Risk calculators and risk factors for Ibopamine

Healthcare Provider Resources

Symptoms of Ibopamine

Causes & Risk Factors for Ibopamine

Diagnostic studies for Ibopamine

Treatment of Ibopamine

Continuing Medical Education (CME)

CME Programs on Ibopamine


Ibopamine en Espanol

Ibopamine en Francais


Ibopamine in the Marketplace

Patents on Ibopamine

Experimental / Informatics

List of terms related to Ibopamine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Ibopamine is a sympathomimetic drug, designed as a prodrug of epinine, used in ophthalmology.[1] It induces mydriasis.[2] It also has been investigated for use in the treatment of congestive heart failure.[3]

It acts on D1[4][5] and α receptors as an agonist.[6]

Ibopamine was first prepared by Casagrande and co-workers.[7]


  1. Magacho L, Costa ML, Dessimoni A, de Avila MP (2006). "Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability". Arq Bras Oftalmol. 69 (5): 695–9. doi:10.1590/S0004-27492006000500015. PMID 17187138.
  2. Marchini G, Babighian S, Tosi R, Perfetti S, Bonomi L (June 2001). "Effects of 2% ibopamine on pupil, refraction, anterior segment anatomy and intraocular pressure". J Ocul Pharmacol Ther. 17 (3): 215–23. doi:10.1089/108076801750295254. PMID 11436942.
  3. van Veldhuisen DJ, Man in 't Veld AJ, Dunselman PH; et al. (November 1993). "Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)". J. Am. Coll. Cardiol. 22 (6): 1564–73. doi:10.1016/0735-1097(93)90579-P. PMID 7901256.
  4. Metra M, Missale C, Spano PF, Cas LD (May 1995). "Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine". J. Cardiovasc. Pharmacol. 25 (5): 732–40. doi:10.1097/00005344-199505000-00008. PMID 7630152.
  5. Lieverse AG, Girbes AR, Van Veldhuisen DJ; et al. (July 1995). "The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure". Eur. Heart J. 16 (7): 937–42. PMID 7498209.
  6. "IngentaConnect Ibopamine Stimulates -Adrenergic Receptors and D1 Dopaminergic Re..."
  7. C. Casagrande, F. Santangelo, C. Saini, F. Doggi, F. Gerli and O. Cerri (1986). "Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines-synthesis of ibopamine metabolites." Arzneimittelforschung 36 291-303.

Template:Cardiac stimulants excluding cardiac glycosides Template:Mydriatics and cycloplegics